PF599 EFFICACY OF BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH CARFILZOMIB-REFRACTORY MYELOMA IN THE UK NCRI CARDAMON TRIAL
Elizabeth H. Phillips(University of Manchester), Kwee Yong(CRUK Lung Cancer Centre of Excellence), William Wilson(Cancer Research UK), Sarah Arnott(Medway Maritime Hospital), Jonathan Sive(University College London Hospitals NHS Foundation Trust), James D. Cavenagh(National Health Service), Laura Clifton‐Hadley(Cancer Research UK), Ceri Bygrave(Cardiff and Vale University Health Board), Matthew Streetly(King's College - North Carolina), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Bhuvan Kishore(National Health Service), Syeda Fatima Hassan(King's College - North Carolina), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Nivette Braganza(Cancer Research UK), Michael A. Chapman(Toronto Metropolitan University), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Sally Moore(University College Hospital), A. Virchis(Cardiff and Vale University Health Board), Reuben Benjamin(King's College London), F. Willis(Barts Health NHS Trust), Guido Nador(Oxford University Hospitals NHS Trust)
Cited by 0
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
|Cancer Cell|2014|1k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719